MRNS News and Press, Marinus Pharmaceuticals Inc. From 07/27/23

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2023 on August 10, 2023. The Company will ...

2023-06-22 17:55:52 ET Summary Marinus Pharmaceuticals has pivoted from postpartum depression to focus on seizure disorders, leading to FDA approval for Ztalmy (ganaxolone) for treating Cyclin-dependent Kinase-like 5 Deficiency Disorder (CDD) seizures. The company is exploring gan...

2023-06-21 16:57:40 ET Marinus Pharmaceuticals ( NASDAQ: MRNS ) said Wednesday that the United States Patent and Trademark Office has granted a new method of use patent for intravenous ganaxolone in the treatment of status epilepticus, expiring in 2040. The company said ...

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the United States Patent and Trademark Office (USPTO) has granted a new method of use patent for intravenous (IV) gana...

2023-06-15 07:51:04 ET Mersana Therapeutics ( NASDAQ: MRSN ) lost ~60% pre-market Thursday after announcing that the FDA issued a partial clinical hold halting the enrollment in its UP-NEXT and UPGRADE-A trials for lead asset UpRi in platinum-sensitive ovarian cancer. The ...

2023-05-26 08:20:12 ET A committee of the European Medicines Agency (EMA) recommended the approval of Marinus Pharmaceuticals' ( NASDAQ: MRNS ) Ztalmy (ganaxolone) to treat epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder...

The European Commission decision is expected within 67 days of the CHMP opinion Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the Committee for Medicinal...

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Sarah Noonberg, M.D., Ph.D., to its Board of Directors. “Sarah is an accomplished healthcare ...

2023-05-11 13:58:03 ET Marinus Pharmaceuticals, Inc. (MRNS) Q1 2023 Results Conference Call May 11, 2023 08:30 AM ET Company Participants Sasha Damouni Ellis - Vice President of Corporate Affairs and Investor Relations Scott Braunstein - Chairman and Chief Executive ...

2023-05-11 07:07:12 ET Marinus Pharmaceuticals press release ( NASDAQ: MRNS ): Q1 GAAP EPS of -$0.67 beats by $0.13 . Revenue of $10.38M (-26.8% Y/Y) beats by $5.47M . For the fiscal year 2023, the Company maintains its prior guidance with expected ZTALMY ...